by jmanor | Aug 25, 2023 | White Papers
This policy brief analyzes the impact of regulatory and legislative changes within the Inflation Reduction Act (IRA) on medical R&D and patient health with respect to small molecule drugs. Initial evidence potentially suggests that the cutbacks in R&D have...
by jmanor | Jun 7, 2023 | White Papers
Historically, Medicare has reimbursed drugs approved by the Food and Drug Administration (FDA) including drugs granted accelerated approval. In 2021, FDA granted accelerated approval to plaque-targeting treatments for Alzheimer’s disease (AD), but the Centers for...
by jmanor | Apr 3, 2023 | White Papers
The Biden administration has made reducing health disparities a major goal of its health care agenda. This paper provides analysis of whether and how biopharmaceutical innovation has historically reduced disparities in health outcomes and how reducing such innovation...
by jmanor | Feb 15, 2023 | White Papers
This paper provides the first quantitative economic models of pharmacy benefit management (PBM) regulation. Indeed, few economic models of the pharmaceutical industry even acknowledge that drug benefits are managed and that companies specialize in benefit management....
by jmanor | Nov 29, 2022 | White Papers
Despite the large disease burden imposed by Alzheimer’s disease (AD), little quantitative evidence exists on the aggregate value stemming from innovation slowing the progression of the disease. To fill this gap, this paper uses the existing evidence base to assess the...
